Kura Oncology (KURA) Revenue (2025 - 2026)
Kura Oncology (KURA) reported Revenue of $18.3 million for Q1 2026, up 29.47% year-over-year from $14.1 million in Q1 2025, and up 5.36% on a QoQ basis from $17.3 million in Q4 2025.
Kura Oncology (KURA) has 2 years of Revenue data on file, last reported at $18.3 million in Q1 2026.
- Quarterly Revenue rose 29.47% year-over-year to $18.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.6 million (changed N/A YoY) and the FY2025 annual result came in at $67.5 million, up 25.24% from the prior year.
- Revenue climbed to $18.3 million in Q1 2026 per KURA's latest filing, from $17.3 million in the prior quarter.
- Across five years, Revenue topped out at $20.8 million in Q3 2025 and bottomed at $14.1 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 18.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.27 Mn |
| Dec 31, 2025 | 17.34 Mn |
| Sep 30, 2025 | 20.75 Mn |
| Jun 30, 2025 | 15.29 Mn |
| Mar 31, 2025 | 14.11 Mn |